Zymeworks Receives FDA Fast Track Designation for ZW191
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ZYME?
Source: NASDAQ.COM
- FDA Fast Track Designation: Zymeworks announced that its antibody-drug conjugate ZW191 has received Fast Track designation from the FDA for the treatment of advanced or metastatic platinum-resistant ovarian cancer patients, marking a significant advancement in the company's oncology portfolio.
- Targeted Therapy Potential: ZW191 targets the folate receptor-a protein, which is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and about 70% of lung adenocarcinomas, indicating its broad applicability.
- Unique Design Advantages: The design of ZW191 allows it to effectively internalize into FRa-expressing cells and release the novel proprietary payload ZD06519, which has the potential to kill tumor cells, thereby providing new treatment options for patients.
- Clinical Trial Progress: Zymeworks is currently conducting a Phase 1 clinical study of ZW191 to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, which will inform future development strategies based on the data collected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZYME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZYME
Wall Street analysts forecast ZYME stock price to rise
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.210
Low
30.00
Averages
35.55
High
42.00
Current: 24.210
Low
30.00
Averages
35.55
High
42.00
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zymeworks' Investigational Drug ZW191 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Zymeworks' investigational drug ZW191 has received Fast Track designation from the FDA for treating advanced or metastatic platinum-resistant ovarian cancer, highlighting the program's potential to address significant unmet medical needs.
- Clinical Trial Progress: A Phase I trial of ZW191 in patients with advanced solid tumors is currently underway, which is expected to expedite the drug development process and provide faster treatment options for patients.
- Positive Market Reaction: Following the announcement, Zymeworks' stock price rose over 3% to $24.73 in premarket trading on Monday, indicating investor optimism regarding the drug's prospects.
- Broad Applicability: As an antibody-drug conjugate targeting folate receptors, ZW191 shows potential for treating various tumor types, particularly benefiting approximately 75% of high-grade serous ovarian carcinoma patients, indicating its wide applicability in the treatment landscape.
See More
Zymeworks Receives FDA Fast Track Designation for ZW191
- FDA Fast Track Designation: Zymeworks announced that its antibody-drug conjugate ZW191 has received Fast Track designation from the FDA for the treatment of advanced or metastatic platinum-resistant ovarian cancer patients, marking a significant advancement in the company's oncology portfolio.
- Targeted Therapy Potential: ZW191 targets the folate receptor-a protein, which is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and about 70% of lung adenocarcinomas, indicating its broad applicability.
- Unique Design Advantages: The design of ZW191 allows it to effectively internalize into FRa-expressing cells and release the novel proprietary payload ZD06519, which has the potential to kill tumor cells, thereby providing new treatment options for patients.
- Clinical Trial Progress: Zymeworks is currently conducting a Phase 1 clinical study of ZW191 to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, which will inform future development strategies based on the data collected.
See More
ZW191 Receives FDA Fast Track Designation for Ovarian Cancer Treatment
- FDA Fast Track Designation: ZW191, an antibody-drug conjugate, has received Fast Track designation from the FDA for treating advanced or metastatic platinum-resistant ovarian cancer, highlighting its potential to address significant unmet medical needs.
- Clinical Trial Progress: Currently, ZW191 is undergoing a Phase 1 clinical trial enrolling patients with advanced solid tumors to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, aiming to inform future development strategies with robust data.
- Targeted Treatment Advantage: The folate receptor α targeted by ZW191 is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, indicating its potential to benefit a broad patient population without the need for biomarker selection.
- Strengthened Company Strategy: This designation further reinforces Zymeworks' expertise in ADC development, expected to accelerate the advancement of ZW191 and enhance the company's competitive position in the oncology market.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
Zymeworks (ZYME.US) Insider Plans to Sell $6.13 Million Worth of Common Stock via Form 144
Stock Sale Announcement: Jeffery T.L.S. Smith plans to sell 247.33k shares of Zymeworks (ZYME.US) on March 6, with an estimated market value of around $6.13 million.
Reduction in Holdings: Since January 5, 2026, Smith has reduced his shareholding in Zymeworks by 19,848 shares, valued at approximately $475.56k.
See More
Zymeworks' Investigational Drug ZW191 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Zymeworks' investigational drug ZW191 has received Fast Track designation from the FDA for treating advanced or metastatic platinum-resistant ovarian cancer, highlighting the program's potential to address significant unmet medical needs.
- Clinical Trial Progress: A Phase I trial of ZW191 in patients with advanced solid tumors is currently underway, which is expected to expedite the drug development process and provide faster treatment options for patients.
- Positive Market Reaction: Following the announcement, Zymeworks' stock price rose over 3% to $24.73 in premarket trading on Monday, indicating investor optimism regarding the drug's prospects.
- Broad Applicability: As an antibody-drug conjugate targeting folate receptors, ZW191 shows potential for treating various tumor types, particularly benefiting approximately 75% of high-grade serous ovarian carcinoma patients, indicating its wide applicability in the treatment landscape.
See More
Zymeworks Receives FDA Fast Track Designation for ZW191
- FDA Fast Track Designation: Zymeworks announced that its antibody-drug conjugate ZW191 has received Fast Track designation from the FDA for the treatment of advanced or metastatic platinum-resistant ovarian cancer patients, marking a significant advancement in the company's oncology portfolio.
- Targeted Therapy Potential: ZW191 targets the folate receptor-a protein, which is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and about 70% of lung adenocarcinomas, indicating its broad applicability.
- Unique Design Advantages: The design of ZW191 allows it to effectively internalize into FRa-expressing cells and release the novel proprietary payload ZD06519, which has the potential to kill tumor cells, thereby providing new treatment options for patients.
- Clinical Trial Progress: Zymeworks is currently conducting a Phase 1 clinical study of ZW191 to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, which will inform future development strategies based on the data collected.
See More
ZW191 Receives FDA Fast Track Designation for Ovarian Cancer Treatment
- FDA Fast Track Designation: ZW191, an antibody-drug conjugate, has received Fast Track designation from the FDA for treating advanced or metastatic platinum-resistant ovarian cancer, highlighting its potential to address significant unmet medical needs.
- Clinical Trial Progress: Currently, ZW191 is undergoing a Phase 1 clinical trial enrolling patients with advanced solid tumors to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, aiming to inform future development strategies with robust data.
- Targeted Treatment Advantage: The folate receptor α targeted by ZW191 is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, indicating its potential to benefit a broad patient population without the need for biomarker selection.
- Strengthened Company Strategy: This designation further reinforces Zymeworks' expertise in ADC development, expected to accelerate the advancement of ZW191 and enhance the company's competitive position in the oncology market.
See More
BETA Technologies Reports Disappointing Q4 Results
- Earnings Miss: BETA Technologies reported a Q4 loss of $2.02 per share, significantly worse than the analyst consensus estimate of a loss of $0.84, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Beat: Despite the significant losses, the company achieved quarterly sales of $11.133 million, surpassing the analyst consensus of $7.859 million, suggesting some resilience in market demand that could lay the groundwork for future growth.
- Stock Reaction: In pre-market trading, BETA's shares fell 3.1% to $18.67, reflecting a negative investor response to the earnings report, which may lead to increased liquidity pressure in the short term.
- Market Sentiment: The overall market sentiment is bearish, with Dow futures down over 1%, indicating investor concerns about the economic outlook, which could further impact BETA Technologies and other related stocks.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
Zymeworks (ZYME.US) Insider Plans to Sell $6.13 Million Worth of Common Stock via Form 144
Stock Sale Announcement: Jeffery T.L.S. Smith plans to sell 247.33k shares of Zymeworks (ZYME.US) on March 6, with an estimated market value of around $6.13 million.
Reduction in Holdings: Since January 5, 2026, Smith has reduced his shareholding in Zymeworks by 19,848 shares, valued at approximately $475.56k.
See More
